Omnia SanaCommon names in 31 European languages →
The complete database record: 2 documented constituents, 4 pharmacological actions, 8 traditional / indicated uses, with 20 cited sources.
Botanical Description
Large deciduous tree, to 25-30 m, with a broad domed crown and stout, upward-arching branches. The leaves are opposite and palmately compound, with five to seven large, obovate, toothed leaflets radiating from a long stalk. In spring the tree bears large, showy, upright pyramidal flower spikes ('candles') of white flowers marked with yellow or pink at the base. The glossy brown seeds ('conkers') develop inside a spiky green husk and fall in autumn.[1]
Habitat & Distribution
Native to the Balkan Peninsula, and widely planted and naturalised as an ornamental and avenue tree across temperate Europe, North America and elsewhere.[1]
Harvesting
Key Constituents
The active mixture responsible for the venotonic and anti-oedematous effects; extracts are standardised to it. Escin is available as oral drages and a transdermal gel, with efficacy shown in chronic venous insufficiency and blunt-trauma injury.
Pharmacological Actions
Anti-oedematous and anti-inflammatory - escin reduces vascular permeability in inflamed tissue and exerts venotonic effects on veins
Anti-oedematous and anti-inflammatory - escin reduces vascular permeability in inflamed tissue and exerts venotonic effects on veins
Escin, the triterpene saponin of Aesculus hippocastanum, induces apoptosis and cell-cycle arrest and chemosensitizes breast, hepatocellular, lung and pancreatic cancer cells (preclinical, including in vivo xenograft models).
Traditional & Indicated Uses
inferred from anti-inflammatory action
Escin shows antiproliferative and pro-apoptotic activity and enhances chemotherapy/immunotherapy efficacy in breast (MCF-7), hepatocellular, lung and pancreatic cancer models; it modulates NF-kappaB, p53, p38 MAPK/ERK and PD-L1 (preclinical).
more plants for cancer (anticancer research) →detailed sources →
Relief of haemorrhoid symptoms (venotonic)
inferred from anti-inflammatory action
Chronic venous insufficiency - reduces leg pain, swelling (oedema), heaviness and itching; supports varicose veins
inferred from anti-inflammatory action
Chronic venous insufficiency - reduces leg pain, swelling (oedema), heaviness and itching; supports varicose veins
more plants for swelling / fluid retention →detailed sources →
Chronic venous insufficiency - reduces leg pain, swelling (oedema), heaviness and itching; supports varicose veins
Traditional Use & History
Horse chestnut seed has a long folk history as a remedy for varicose veins, haemorrhoids and 'heavy legs', and was also used topically for rheumatic pain and bruising. Modern use is almost exclusively as a standardised seed extract for chronic venous insufficiency, confirming this traditional venous-support reputation.[1]
Preparations
Dosage
Clinical studies commonly use extracts standardised to around 100-150 mg escin daily, in divided doses. Educational reference only, not a prescription.
The EU herbal monograph gives semi-solid dosage forms containing the equivalent of 0.4% triterpene glycosides calculated as protoaescigenin (or, depending on the preparation, 0.85-20% herbal preparation), applied as a thin layer to the affected area 1-3 times daily, in adults and elderly. Educational reference only, not a prescription.
Safety, Cautions & Contraindications
Use only standardised, processed seed extract. Raw conkers, leaves and bark contain toxic esculin and can cause poisoning - never eat raw horse chestnut.
May increase bleeding risk, so use caution with anticoagulant/antiplatelet medicines; use caution in kidney disease and avoid in pregnancy and breastfeeding.
Herb-Drug Interactions
Harvest Readiness
[10]
External Identifiers
References & Sources
- Idris, S. and Mishra, A. and Khushtar, M (2020) 'Phytochemical, ethnomedicinal and pharmacological applications of escin from Aesculus hippocastanum L. towards future medicine', Journal of Basic and Clinical Physiology and Pharmacology, 31(5). doi:10.1515/jbcpp-2019-0115 Meta-analysis / review
https://doi.org/10.1515/jbcpp-2019-0115 - Penaranda Figueredo, F.A. and Vicente, J. and Barquero, A.A. and Bueno, C.A (2024) 'Aesculus hippocastanum extract and the main bioactive constituent beta-escin as antivirals agents against coronaviruses, including SARS-CoV-2', Scientific Reports, 14(1), pp. 6418. doi:10.1038/s41598-024-56759-y Preclinical
https://doi.org/10.1038/s41598-024-56759-y - Idris, S. and Mishra, A. and Khushtar, M (2023) 'Phytochemical Estimation and Therapeutic Amelioration of Aesculus hippocastanum L. Seeds Ethanolic Extract in Gastric Ulcer in Rats Possibly by Inhibiting Prostaglandin Synthesis', Chinese Journal of Integrative Medicine, 29(9), pp. 818-824. doi:10.1007/s11655-023-3734-9 Preclinical
https://doi.org/10.1007/s11655-023-3734-9 - Quarta, S. and Santarpino, G. and Carluccio, M.A. and Calabriso, N. and Scoditti, E. and Siculella, L. and Damiano, F. and Maffia, M. and Verri, T. and De Caterina, R. and Massaro, M (2022) 'Analysis of the Anti-Inflammatory and Anti-Osteoarthritic Potential of Flonat Fast, a Combination of Plant Extracts, Bromelain and Escin (Aesculus hippocastanum), Evaluated in In Vitro Models of Inflammation Relevant to Osteoarthritis', Pharmaceuticals, 15(10), pp. 1263. doi:10.3390/ph15101263 Preclinical
https://doi.org/10.3390/ph15101263 - Owczarek, A. and Kolodziejczyk-Czepas, J. and Wozniak-Serwata, J. and Magiera, A. and Kobiela, N. and Wasowicz, K. and Olszewska, M.A (2021) 'Potential Activity Mechanisms of Aesculus hippocastanum Bark: Antioxidant Effects in Chemical and Biological In Vitro Models', Antioxidants, 10(7), pp. 995. doi:10.3390/antiox10070995 Preclinical
https://doi.org/10.3390/antiox10070995 - Cheong, D.H.J., Arfuso, F., Sethi, G., Wang, L., Hui, K.M., Kumar, A.P. and Tran, T (2018) 'Molecular targets and anti-cancer potential of escin', Cancer Letters. doi:10.1016/j.canlet.2018.02.027 Preclinical
https://doi.org/10.1016/j.canlet.2018.02.027 - Pittler, M.H. and Ernst, E (2012) 'Horse chestnut seed extract for chronic venous insufficiency', Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD003230.pub4 Meta-analysis / review
https://doi.org/10.1002/14651858.CD003230.pub4 - Gallelli, L (2019) 'Escin: a review of its anti-edematous, anti-inflammatory, and venotonic properties', Drug Design, Development and Therapy, pp. 3425--3437. doi:10.2147/DDDT.S207720 Preclinical
https://doi.org/10.2147/DDDT.S207720 - Wu, X.J., Zhang, M.L., Cui, X.Y., Gao, F., He, Q., Li, X.J., Zhang, J.W., Fawcett, J.P. and Gu, J.K (2011) 'Comparative pharmacokinetics and bioavailability of escin Ia and isoescin Ia after administration of escin and of pure escin Ia and isoescin Ia in rat', Journal of Ethnopharmacology, 139(1), pp. 201--206. doi:10.1016/j.jep.2011.11.003 Preclinical
https://doi.org/10.1016/j.jep.2011.11.003 - Grieve, M (1931) 'Chestnut, Horse (Aesculus hippocastanum) — A Modern Herbal'. Available at: https://botanical.com/botanical/mgmh/c/chehor58.html Traditional / reference
https://botanical.com/botanical/mgmh/c/chehor58.html - European Medicines Agency (HMPC) (2023) 'European Union herbal monograph on Aesculus hippocastanum L., semen, Revision 1'. Available at: https://www.ema.europa.eu/en/documents/herbal-monograph/european-union-herbal-monograph-aesculus-hippocastanum-l-semen-final-revision-1_en.pdf Traditional / reference
https://www.ema.europa.eu/en/documents/herbal-monograph/european-union-herbal-monograph-aesculus-hippocastanum-l-semen-final-revision-1_en.pdf - Cheong, D.H.J., Arfuso, F., Sethi, G., Wang, L., Hui, K.M., Kumar, A.P. and Tran, T (2018) 'Molecular targets and anti-cancer potential of escin', Cancer Letters, pp. 1--8. doi:10.1016/j.canlet.2018.02.027 Preclinical
https://doi.org/10.1016/j.canlet.2018.02.027 - Mazrouei, R. and Raeisi, E. and Lemoigne, Y. and Heidarian, E (2019) 'Activation of p53 Gene Expression and Synergistic Antiproliferative Effects of 5-Fluorouracil and beta-escin on MCF7 Cells', Journal of Medical Signals and Sensors, 9(3), pp. 196-203. doi:10.4103/jmss.JMSS_44_18 Preclinical
https://doi.org/10.4103/jmss.JMSS_44_18 - Yuan, Y. and Wang, P. and Chen, S. and Cao, Z. and Ojha, S.C. and Sun, C. and Wang, G. and Wang, Z. and Gu, J. and Kang, J. and Xue, X (2025) 'Escin inhibits PD-L1 expression by suppressing the p38 MAPK/ERK signalling pathways and synergistically enhances PD-1 inhibitor efficacy in hepatocellular carcinoma', Phytomedicine, 149, pp. 157532. doi:10.1016/j.phymed.2025.157532 Preclinical
https://doi.org/10.1016/j.phymed.2025.157532 - Hussain, Y. and Singh, J. and Meena, A. and Sinha, R.A. and Luqman, S (2023) 'Escin enhanced the efficacy of sorafenib by autophagy-mediated apoptosis in lung cancer cells', Phytotherapy Research, 37(10), pp. 4819-4837. doi:10.1002/ptr.7948 Preclinical
https://doi.org/10.1002/ptr.7948 - Rimmon, A. and Vexler, A. and Berkovich, L. and Earon, G. and Ron, I. and Lev-Ari, S (2013) 'Escin Chemosensitizes Human Pancreatic Cancer Cells and Inhibits the Nuclear Factor-kappaB Signaling Pathway', Biochemistry Research International, 2013, pp. 251752. doi:10.1155/2013/251752 Preclinical
https://doi.org/10.1155/2013/251752 - Domanski, D., Zegrocka-Stendel, O., Perzanowska, A., Dutkiewicz, M., Kowalewska, M., Grabowska, I., Maciejko, D., Fogtman, A., Dadlez, M. and Koziak, K (2016) 'Molecular Mechanism for Cellular Response to beta-Escin and Its Therapeutic Implications', PLoS One, 11(10). doi:10.1371/journal.pone.0164365 Preclinical
https://doi.org/10.1371/journal.pone.0164365 - Gloviczki, M.L., Kakkos, S.K., Urbanek, T., Chuback, J. and Nicolaides, A (2025) 'The role of venoactive compounds in the treatment of chronic venous disease', Journal of Vascular Surgery: Venous and Lymphatic Disorders, 13(5). doi:10.1016/j.jvsv.2025.102258 Preclinical
https://doi.org/10.1016/j.jvsv.2025.102258 - Santiago, F.R., Grillo, L., Amore, M., Carmelino, C., Trejo, J.M.R. and Ulloa, J.H (2026) 'Venoactive drugs in the management of chronic venous disease: A critical appraisal of the evidence and comparison with international guidelines', Vascular Pharmacology. doi:10.1016/j.vph.2026.107614 Preclinical
https://doi.org/10.1016/j.vph.2026.107614 - Pittler, M.H. and Ernst, E (2006) 'Horse chestnut seed extract for chronic venous insufficiency', Cochrane Database of Systematic Reviews, 2006(1), pp. CD003230. doi:10.1002/14651858.CD003230.pub3 Meta-analysis / review
https://doi.org/10.1002/14651858.CD003230.pub3
Selected studies & references
All 18 studies in the Knowledge Finder →
This profile is assembled automatically from the Omnia Sana plant database, which we curate by hand. How this site is built.